$0.00
Shopping Cart
Facebook-f Instagram
Donate

Clinical Trial Record

Return to Clinical Trials

A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

2015-03

2016-09

2016-09

20

Study Overview

A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.

Patients diagnosed with unresectable pancreatic cancer who may or may not have had prior chemotherapy or radiation therapy may be eligible to enroll in this dose escalation study to determine the maximum tolerated dose of gemcitabine to be delivered locally to the pancreatic tumors using the RenovoCath R120 catheter. Patients enrolled may receive up to 8 catheterizations for delivering gemcitabine directly to the pancreatic tumors starting at a reduced dose( 1/4 of standard i.v. gemcitabine dose), then every two doses, increase the dose by 25% if there are no toxicities up to a maximum dose of 1000 mg/m2. There are four cycles, with two doses per cycle. Imaging studies will be conducted as well as assessment for standard, myelosuppresive and gastric toxicities will be assessed. Pain will also be measured throughout the study.

  • Pancreatic Cancer
  • DRUG: Gemcitabine, local delivery
  • RR1

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2014-09-08  

2018-12-06  

2021-04-14  

2014-09-10  

2021-04-14  

2021-05-07  

2014-09-11  

2021-05-07  

2021-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Other

Allocation:
Non Randomized

Interventional Model:
Sequential

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
OTHER: Gemcitabine, Local Delivery (Dose 1)

Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose

DRUG: Gemcitabine, local delivery

  • Intra-arterial targeted drug delivery
OTHER: Gemcitabine, Local Delivery (Dose 2)

Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose

DRUG: Gemcitabine, local delivery

  • Intra-arterial targeted drug delivery
OTHER: Gemcitabine, Local Delivery (Dose 3)

Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose

DRUG: Gemcitabine, local delivery

  • Intra-arterial targeted drug delivery
OTHER: Gemcitabine, Local Delivery (Dose 4)

Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose

DRUG: Gemcitabine, local delivery

  • Intra-arterial targeted drug delivery
Primary Outcome MeasuresMeasure DescriptionTime Frame
Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the PancreasMaximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter. One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.1 week post treatment
Secondary Outcome MeasuresMeasure DescriptionTime Frame
CA19-9 Tumor ReductionMeasurements of CA19-9 tumor marker are measured pre-treatment and at various time points (starting with one week) post treatment.1 week after treatment

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    Subjects will be eligible to participate in the study if all of the following criteria are met:
    1. Males and female subjects 18 years of age and older. 2. Subjects with locally advanced unresectable adenocarcinoma (cytological or histologic proof required) of the pancreas.. Patients with islet cell tumors are not eligible. 3. No clinical evidence of distant metastases, excluding single liver metastasis and local lymph node involvement. Patients with more than a single liver metastasis and/or other metastases who have already failed systemic chemotherapy and/or are on a break from systemic chemotherapy who are not surgical candidates can also qualify for this study. 4. Karnofsky Performance Status (KPS) >60. 5. Adequate renal, and bone marrow function described as:
    1. Leukocytes ≥ 3,000/uL 2. Absolute neutrophil count ≥ 1,500/uL 3. Platelets ≥100,000/uL 4. Serum creatinine ≥2.0 mg/dL. Creatinine less than or equal to 1.5 mg/dL or creatinine clearance greater than 40 mL/min/1.73 m2 for patients with creatinine levels above institutional normal, as calculated by the Cockcroft Gault formula. 5. Hemoglobin ≥8.5 g/dL (may be receiving supportive therapy) 6. PT/PTT (WNL) 6. Adequate Hepatic function (endoscopic or percutaneous drainage as needed) described as:
    1. Total bilirubin ≤3 times UNL (less than or equal to 2 mg/dL) 2. AST (SGOT)/ALT (SGPT) ≤ 5 times ULN or ≤5 times ULN in the setting of liver metastases. 3. Lipase and Amylase within normal limits. 7. Capable of understanding the purpose and risks of the study and willing to provide written informed consent and to comply with the procedures
    Exclusion Criteria:
    Subjects will be excluded from participation in the study if any of the following criteria are met:
    1. Have a known sensitivity to gemcitabine. 2. Identification of metastatic disease, with the exception of single liver metastases or local lymph node involvement. Patients with more than a single liver metastasis and/or other metastases who have already failed systemic chemotherapy and/or are on a break from systemic chemotherapy who are not surgical candidates can also qualify for this study. 3. Evidence of coagulopathy. 4. Inability or unwillingness to comply with study procedures and/or follow-up procedures. 5. Evidence of infection or other coexisting medical condition, which in the opinion of the investigator would preclude administration of gemcitabine. 6. Patients with uncontrolled congestive heart failure, unstable angina and myocardial infarction within 3 months. 7. Female patient who is pregnant, nursing or planning on becoming pregnant. 8. Current enrollment and participation in another clinical study or prior exposure to an investigational agent within 12 weeks or 5 half-lives (whichever is longer) of anticipated dosing on Day 1 of this study. 9. Have known brain metastases. 10. Have had any major surgery within four weeks of enrollment. 11. Have any clinically detectable ascites. 12. Have uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. 13. Have serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol. 14. Other invasive malignancies within the past 3 years (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or prostate cancer) not approved by the Medical Monitor (contact MM in event of prior diagnosis with malignancy to discuss enrollment status). 15. Have had any chemotherapy or systemic corticosteroids within 2 weeks of study entry. 16. Have acquired, hereditary or congenital immunodeficiency's including cellular immunodeficiencies, hypogammaglobulinemia and dysgammaglobulinemia or hepatitis. 17. Have a prior history of a documented hemolytic event. 18. Is HIV-positive or Hepatitis positive.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • PRINCIPAL_INVESTIGATOR: Jiali Li, MD, El Camino Hospital

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    Treat yourself

    Let Us Take Care Of You

    BOOK AN APPOINTMENT ⟶

    About

    Events

    Fundraising

    Contact Us

    Facebook-f Instagram

    NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

    The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

    Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved

    Make-A-Will Month

    Learn More
    Donate Now Online
    Other Ways to Donate